natgillin/translations-raw huggingface dataset:
A suitable reducing agent is, for example, a hydride reducing agent, for example formic acid, an alkali metal aluminium hydride such as lithium aluminium hydride, or, suitably, an alkali metal borohydride such as sodium borohydride, sodium cyanoborohydride, sodium triethylborohydride, sodium trimethoxyborohydride and sodium triacetoxyborohydride. 
sadržava N-metil skupinu, odgovarajući spoj koji sadržava N-H skupinu može reagirati sa formaldehidom u prisutnosti odgovarajućeg reducirajućeg agensa, Prikladni reducirajući agens jest, na primjer, hidrid, na primjer, mravlja kiselina, aluminij hidrid alkalijskog metala, poput litij-aluminij-hidrida, ili prikladno, borhidird alkalijskog metala poput natrij- borhidrida, natrij-cijanoborhidrida, natrij trietilborhidirida, natrij trimetoksiborhidirda i natrij acetoksiborhidrida.
The fuel element was made from a mixture of 90% PCB-G activated carbon and 10% SCMC as a binder at about 5000 pounds (2273 kg) of applied load. 
Gorivi element je napravljen od smjese 90% PCB-G aktiviranog ugljika 1 10% NKMC kao vezivnog sredstva pri primjenjenom opterećenju od 2273 kg.
the variable light chain sequence of SEQ ID NO: 95 and variable heavy chain sequence of SEQ ID NO: 109; 
(k) varijabilno područje slabog lanca od sekvence SEQ ID NO: 95, i varijabilno područje jakog lanca od sekvence SEQ ID NO: 109;
Mass directed autoprep refers to methods where the material was purified by high performance liquid chromatography on a HPLCABZ+ 5µm column (5cmx10mm i.d.) with 0.1% HCO2H in water and 95% MeCN, 5% water (0.5% HCO2H) utilising gradient elution at a flow rate of 8ml minutes-1. 
Maseno ovisna samopriprava odnosi se na postupke gdje je materijal pročišćen visokodjelotvornom tekućinskom kromatografijom na stupcu HPLCABZ+ 5 um (5 cm x 10 mm, unutarnji promjer), uz eluiranje s 0,1 % HCO;H u vodi i 95 % MeCN, 5 % vodom (0,5 % HCO»H), uz upotrebu elucijskog gradijenta, pri brzini protoka od 8 ml/min.
The configuration at C-7 is 7aand at C-17a the configuration is 17aB. 
Konfiguracija na C-7 je 7a, ana C-17a je konfiguracija 17af.
Effects on Learning 
Primjer 9: Učinak na učenje
The use of the system according to claim 1, wherein the second composition of the second component of the system further comprises the at least one penetration-promoting, anti-inflammatory agent selected from a group of salicylates. 
Upotreba sustava u skladu sa zahtjevom 1, naznačena time, što se drugi sastav od druge komponente sustava nadalje sastoji od najmanje jednog sredstva promicanja prodiranja, protu upalnog odabranog iz grupe salicilata,
It is contemplated that the compounds will be useful in therapy as pharmaceuticals, in particular for the treatment of neurological and psychiatric disorders associated with glutamate dysfunction in an animal and particularly in a human. 
Uporaba prema zahtjevu 7, naznačena time da poremećaj je shizofrenija. Spoj prema zahtjevu 1, 2, 3 ili 4 naznačen time da je za terapiju neuroloških i psihijatrijskih poremećaja povezanih s glutamatnom disfunkcijom.
Even more preferably, the beverage is beer, most preferably lager beer. 
Čak još poželjnije, piće je pivo, najpoželjnije svijetlo (lager) pivo.
A new intermediate compound selected from the group consisting of 
Novi intermedijerni spoj izabran iz grupe koja se sastoji od
According to another embodiment, the binder is in form of a solution or a dry material, preferably in form of an aqueous solution having a binder concentration from 1 to 70 wt.-%, preferably from 2 to 55 wt.-%, more preferably from 5 to 50 wt.-%, and most preferably from 30 to 50 wt.-%, based on the total weight of the solution. 
Postupak prema zahtjevu 1 ili 2, gdje je vezivo u obliku otopine ili suhog materijala, poželjno u obliku vodene otopine s koncentracijom veziva od 1 do 70% tež., poželjno od 2 do 55% tež., poželjnije od 5 do 50% tež., 1 najpoželjnije od 30 do 50% tež., u odnosu na ukupnu težinu otopine.
9 . FIG. 10 shows a cross-sectional view of the side of the inner part 60 (such as the upper part 6 of FIG. 
Slika 10 prikazuje pogled na poprečni presjek jedne strane unutarnjeg dijela 60 (takve strane kao što je gornji dio 6 iz slike 1) pakiranja 2 koje ima član za držanje koji zahvaća i drži CD ili DVD.
an on rate constant (Kon) to PRLR selected from the group consisting of: at least about 102 M−1s−1; at least about 103 M−1s−1; at least about 104 M−1s−1; at least about 105 M−1s−1; and at least about 106 M−1s−1; as measured by surface plasmon resonance; 
ima konstantu brzine vezanja (Kon) za PRLR odabranu iz skupine koja sadrži: barem oko 102M-1s-1; barem oko 103M-1s-1; barem oko 104M-1s-1; barem oko 105M-1s-1; i barem oko 106M-1s-1; kao što je izmjereno rezonancijom površinskog plazmona;
Compound of any one of claims 1 to 7 in the treatment, prevention or amelioration of pain, wherein the pain is selected from the group consisting of chronic pain, neuropathic pain, inflammatory pain, pain due to osteoarthritis, pain due to arthritis, pain due to rheumatoid arthritis, cancer pain, pain due to spinal cord injury, surgical pain, post-operative pain or acute pain. 
i njegove farmaceutski prihvatljive soli i solvati. Spoj za uporabu prema zahtjevu 15, naznačen time da je bol odabrana iz skupine koja sadrži kroničnu bol, neuropatsku bol, upalnu bol, bol zbog osteoartritisa, bol zbog artritisa, bol zbog reumatoidnog artritisa, bol zbog karcinoma, bol zbog ozljede leđne moždine, operativnu bol, postoperativnu bol ili akutnu bol.
In another preferred embodiment, the binding molecule according to the invention also has neutralizing activity against an influenza virus comprising HA of the H1 subtype, and preferably wherein said binding molecule also has neutralizing activity against an influenza virus comprising HA of the H2, H6 and/or H9 subtype. 
Antitijelo, ili njegov dio koji veže antigen, prema zahtjevu 1, naznačeni time da navedeno antitijelo ili njegov dio koji veže antigen također ima neutralizirajuću aktivnost protiv virusa influence koji sadrži HA podvrste H1, kao HINI, te poželjno time da navedeno antitijelo ili njegov dio koji veže antigen također ima neutralizirajuću aktivnost protiv virusa influence koji sadrži HA podvrste H2, H6 i/ili H9.
A method of scavenging hydrogen sulfide as claimed in any one of claims 7 to 10, wherein said hydrocarbon includes crude oil, fuel oil, sour gas, and asphalts and refined products contained in storage tanks, vessels, pipelines. 
Metoda čišćenja vodik sulfida temeljem bilo kojeg od zahtjeva 7 do 10, pri čemu navedeni ugljikovodik uključuje sirovu naftu, ulje za loženje, sumporovodik i asfalte i rafinirane proizvode sadržanima u tankovima za skladištenje, spremnicima, cjevovodima.
A solution of 4.11 g (18,1 mmol) of periodic acid (H5IO6) was added at once, and then stirred during 48h at room temperature. 
Odjednom se doda otopinu od 4,11 g (18,1 mmolova) perjodne kiseline (H5IOy«) i zatim se miješa tijekom 48h pri sobnoj temperaturi.
Netupitant for use according to claims 1-8, comprising treating nausea and vomiting in response to highly emetogenic chemotherapy during the acute phase, or in response to highly emetogenic chemotherapy during the delayed phase. 
Netupitant za uporabu u skladu s patentnim zahtjevima 1-7, obuhvaća liječenje mučnine 1 povraćanja kao odgovora na vrlo emetogenu kemoterapiju za vrijeme akutne faze, ili kao odgovor na vrlo emetogenu kemoterapiju tijekom odgođene faze.
The set of furniture components as claimed in any one of preceding claims, wherein adjacent outer panel edges (17, 18) in a corner portion are inclined inwardly against the main plane (MP) of the panels. 
Komplet dijelova namještaja prema bilo kojem od prethodnih zahtjeva, naznačen time da su susjedmi vanjski rubovi ploče (17, 18) u kutnom dijelu nagnuti prema unutra prema glavnoj ravnini (MP) ploča.
mg The formulation was prepared by preliminary granulation of the active ingredient, mixing and pressing by standard techniques. First, silicon-coated ascorbic acid and lactose were mixed for 10 minutes in a mixer, wetted with a solution of hydroxypropylmethyl cellulose 2910 in water and granulated for 10 minutes. 
Pripravak je načinjen preliminarnom granulacijom aktivnog sastojka, miješanjem i prešanjem standardnim tehnikama, Prvo, miješani su silikonom-prevučena askorbinska kiselina i laktoza tijekom 10 minuta u mješalici, navlaženi su otopinom hidroksipropilmetil celuloze 2910 u vodi i granulirani tijekom 10 minuta.
provided that when is or then a is 1. 
uz uvjet da kada [image] je [image] ili [image] tada a je 1.
RA is 5-10 membered heteroaryl optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from RCy; or 
RA je 5-10 -člani heteroaril izborno supstituiran sa 1, 2, 3, 4 ili 5 supstituenata nezavisno izabranih od RCy; ili
Alternatively, the type of multiple sclerosis to be treated is relapsing-remitting multiple sclerosis. 
Sastav obuhvaća muramil dipeptid poprečno povezan u mikročesticu za uporabu u liječenju multiple skleroze.
The process of claim 1, wherein the particle number ratio between the water soluble and/or water swellable material particles and the substantially water insoluble polymer particles of the mixing step is in a range of from 1:20 to 1:80. 
Postupak sukladno zahtjevu 1, naznačeno time, da se brojčani odnos čestica topivih materijalnih čestica, koje bubre u vodi i u vodi potpuno netopivih polimernih čestica u koraku miješanja, u tom području od 1:10 do 1:100, ili od 1:20 do 1:80.
A compound according to Claim 1, wherein R1 represents CH3; R2 represents H, 2-F or 3-CN; R3 represents H; R4 represents H or CH3; and R5 represents H. 
Spoj prema zahtjevu 1, naznačen time, da R1 predstavlja CH3; R2 predstavlja H, 2-F ili 3-CN; R3 predstavlja H; R4 predstavlja H ili CH3; a R5 predstavlja H.
represents a substituent, 
predstavlja supstituent,
The detection device of claim 1, wherein the first detectable entity is a metal nanoparticle, metal nanoshell, fluorophore, or colored latex particle. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je prvi detektibilni entitet metalna nanočestica, metal nanoljuska, fluorofor ili obojena čestica od lateksa.
In yet another aspect, the present invention relates to a method for synthesizing an amatoxin, or precursor molecule therefor, comprising the step of (a) coupling compound 6 to hydroxyproline, particularly by reacting compound 6 with a hydroxyproline-preloaded resin, particularly by coupling compound 6 to the free C-terminus of FmocHypOH immobilized on a resin L, for example a tetrahydropyranyl (THP) resin. 
Postupak sinteze amatoksina ili njegove prekursorske molekule, naznačen time, da obuhvaća korak: (a) spajanje spoja 6 s hidroksiprolinom, osobito reakcijom spoja 6 sa smolom prethodno napunjenom hidroksiprolinom, osobito vezanjem spoja 6 sa slobodnim C-krajem FmocHypOH imobiliziranog na smoli L, naročito tetrahidropiranil (THP) smoli. 04 OH A
R4; R5, R6, R7 and R8 are each independently H, CH3, C2H5, linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substituted phenyl, or heterocyclic aromatic or heterocycloalkyl radical; 1, m and n are each independently an integer of from 1 to 5, and in addition n can be 0; and Z is H, SR or -COR, wherein R is linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, or simple or substituted aryl or heterocyclic aromatic or heterocycloalkyl radical. 
, R4, R5, R6, R7 i R8 su svaki nezavisno H, CH3, C2H5, linearni alkil ili alkenil s 1 do 10 atoma ugljika, razgranati ili ciklički alkil ili alkenil s 3 do 10 atoma ugljika, fenil, supstituirani fenil ili heterociklički aromatski ili heterocikloalkilni radikal; l, m i n su svaki nezavisno cijeli broj od 1 do 5, i dodatno n može biti 0; i Z je H, SR ili -COR, pri čemu je R linearni alkil ili alkenil s 1 do 10 atoma ugljika, razgranati ili ciklički alkil ili alkenil s 3 do 10 atoma ugljika, ili jednostavni ili supstituirani aril ili heterociklički aromatski ili heterocikloalkilni radikal.
Y is an ethylene or trimethylene group, provided that when X is a single bond, the moiety (CH2)n—X—Y is a trimethylene or pentamethylene group; and Z is —SO2NR1R2, wherein: 
Y predstavlja etilensku ili trimetilensku skupinu, pod uvjetom da kada X predstavlja jednostruku vezu, polovica (CH>),-X-Y predstavlja skupinu trimetilena ili pentametilena; a Z predstavlja -SO>NR'R", pri čemu
In this context, for example, conventionally manufactured peeled veneers, optionally after a pretreatment such as dyeing or baking of structures, are glued to each other, and the so obtained material is subsequently re-sliced. 
U vezi s tim, na primjer, konvencionalno proizvedeni guljeni furniri s proizvoljnom prethodnom obradom, takvom kao što je bojanje strukture ili termofiksacija strukture, lijepe se jedni na druge i tako dobiveni materijal se nakon toga reže na kriške.
comparing the quantity of Ero1 mRNA and/or protein and XBP1 mRNA and/or protein to the quantity of Ero1 mRNA and/or protein and XBP1 mRNA and/or protein in an unmodified cell clone; and 
usporedbu količine Ero1 mRNA i/ili proteina i XBP1 mRNA i/ili proteina s količinom Ero1 mRNA i/ili proteina i XBP1 mRNA i/ili proteina nemodificiranom staničnom klonu; i
Aqueous slurry according to claim 16 or 17, wherein said surface modified calcium carbonate containing mineral has a BET specific surface area of more than 15 m2/g, and preferably from about 20 m2/g to about 200 m2/g, more preferably from about 30 m2/g to about 150 m2/g, even more preferably from about 40 m2/g to about 100 m2/g. 
HR P20160848 T1 Vodena suspenzija prema jednom od zahtjeva 16 ili 17, naznačena time da navedeni površinski modificirani kalcijev karbonat koji sadrži mineral ima BET specifičnu dodirnu površinu od oko 20 m'/g do oko 200 m'/g, poželjno od oko 30 m"/g do oko 150 m'/g, poželjnije od oko 40 m"/g do oko 100 m/g.
A pharmaceutical composition according to claim 5, wherein hydrophilic polymer is selected from the group comprising carbohydrates like celluloses their derivatives such as ethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxypropylethylcellulose; gums like xanthan gum, guar gum, locust bean gum; alginates; carbomer; poly vinylacetatae, polyvinylalcohol, povidone/polyethylene oxide, acrylic and methacrylic acid copolymers and mixtures thereof. 
Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 5, naznačen time da so hidrofilni polimer za regulaciju brzine oslobađanja odabire između ugljikohidrata poput celuloze, kao što je etil celuloza, hidroksipropil celuloza, hidroksipromilmetil celuloza, hidroksipropiletil celuloza; gume poput ksantanske gume, guar gume, gume iz sjemenki rogača; alginata; ugljika, polivinil acetata, polivinil alkohola, povidon/polietilen oksida, kopolimera akrilne i metakrilne kiseline ili mješavina istih.
A compound with the general formula: where: 
Spoj sa općom formulom: naznačen time da:
wherein Hal, R1 and R2 have the same meaning as in formula (IX), reacting said compound of formula (X) with dithiophosphoric acid O,O-diethyl ester or ammonium sulfide to give a compound of formula (XI): 
(X), gdje Hal, R! i R* imaju isto značenje kao u formuli (IX), gdje navedeni spoj formule (X) reagira s 0,0-dietilnim esterom ditiofosforne kiseline ili amonijevim sulfidom kako bi se dobilo spoj formule (XI):
An isolated nucleic acid encoding a human antibody or antigen-binding fragment thereof that binds to and neutralizes human TGFB1, TGFB2 and TGFB3, wherein the antibody or fragment comprises a heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:1 with a substitution selected from the group consisting of S30A, S30H, S30W, E74A, E74C, E74D, E74F, E74G, E74H, E74L, E74P, E74Q, E74R, E74S, E74T, E74W, and E74Y; and a light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:2. 
Izolirana nukleinska kiselina koja kodira ljudsko protutijelo ili njegov ulomak koji veže antigen koje se veže na i neutralizira ljudski TGFB1, TGFB2 i TGFB3, naznačena time što protutijelo ili ulomak sadrže varijabilnu domenu teškog lanca (VH) koja sadrži sekvencu aminokiseline SEQ ID NO:1 sa supstitucijom odabranom iz skupine koja se sastoji od S30A, S30H, S30W, E74A, E74C, E74D, E74F, E74G, E74H, E74L, E74P, E74Q, E74R, E74S, E74T, E74W, i E74Y; i varijabilnu domenu laganog lanca (VL) koja sadrži sekvencu aminokiseline SEQ ID NO:2.
As seen in Table 1, this compound binds PPARY with high affinity (IC50 = 52 nM) and to PPARa with relatively lower affinity (IC50 = 113). 
Kao što se vidi u Tablici 1, ovaj spoj veže se na PPARy s visokim afinitetom (ICsg = 52 nM), te na PPARa uz relativno niži afinitet (ICs5o = 113).
from 60 wt% to 95 wt% of a diluent selected from the group consisting of monosaccharides, disaccharides, sugar alcohols, and hydrates thereof, cellulose, and microcrystalline cellulose. 
od 60 tež% do 95 tež% punila odabranog iz skupine koju čine monosaharidi, disaharidi, šećerni alkoholi, te njihovi hidrati, celuloza i mikrokristalična celuloza.
A polypeptide comprising an isolated Clostridium difficile toxin A fragment and / or an isolated C . difficile toxin B fragment; and 
polipeptid koji sadrži fragment toksina A iz bakterije Clostridium difficile i fragment izoliranog toksina B iz bakterije C. difficile; i
reacting 2,2-dimethyl-1,3 dioxolane-4-carbaldehyde of formula with a vinyl Grignard reagent to obtain a compound of formula IIb in the form of diastereomeric mixture (R,S+S,S) 
I) reakciju 2,2-dimetil-1,3dioksolan-4-karbaldehida formule dq s vinil Grignardovim reagensom, da bi se dobio spoj formule IIb u obliku dijasteroizomerne smjese (R, S+8, S) on EA Ubit SS
The examples are merely illustrative and do not limit the teaching of this invention and it would be obvious that various modifications or changes in the procedural steps as well as compositions by those skilled in the art without departing from the scope of the invention and shall be consequently encompassed within the ambit and spirit of this approach and scope thereof. 
Primjeri su samo ilustrativni te ne ograničavaju učenja ovog izuma te bi bilo očigledno da različite modifikacije ili promjene u koracima postupka kao i kompozicija od strane vještih stručnjaka bez da se udalje od dosega ovog izuma budu posljedično uključene unutar dosega i duha ovog pristupa i njegova dometa.
The device of the invention comprises a box-shaped collar that is frontally fixed to a traditional wall-recessed box, which acts as fastening element for the component-holder plate that is exactly housed inside the box. 
Uređaj iz ovog izuma sadržava okvir koji ima oblik kutije i koji je s prednje strane pričvršćen na tradicionalno uvučenu kutiju, koja djeluje kao element za učvršćenje ploče za nošenje komponenti i koja se savršeno smješta u kutiju.
A method for the treatment of cancer, which comprises administering to a subject in need thereof a therapeutically-effective amount of the compound or a salt or N-oxide derivative thereof as claimed in claim 1. 
Tvar ili bilo kojeg od patentnih zahtjeva 1 do 12 ili farmaceutski prihvatljiva sol ili njen N-oksid derivat za uporabu u liječenju raka.
Thereby, the layer of the adhesive does not differ from the layer of said pieces what possibly might be disturbing. 
Stoga se sloj ljepila ne razlikuje od sloja navedenih komada što bi možda moglo smetati.
is selected from H, C1-C3 alkyl and cyclohexyl optionally substituted with at least one C1-C3 alkyl group; 
je izabran od H, C1-C3 alkila i cikloheksila izborno supstituiranog s najmanje jednom C1-C3 alkil grupom;
When the lipid component is mixed with the protein component, the resulting suspension is cloudy. 
(ili) početna suspenzija je proizvod postupka koji obuhvaća miješanje lipidne komponente i proteinske komponente;
The method according to claim 7, wherein the flushing step comprises inserting a draw-string through the outer sheath across any remaining filler material deposits, attaching a cleaning element to said draw string and pulling said cleaning element through the outer sheath. 
Postupak sukladno zahtjevu 4, pri čemu korak ispiranja obuhvaća umetanje rastezljive uzice u vanjski plašt (6) preko eventualno preostalih naslaga materijala za ispunu, pričvršćivanje elementa za čišćenje za navedenu uzicu i njegovo provlačenje kroz vanjski plašt (6).
The extended release dosage form of any one of claims 1 to 11, wherein the dosage form comprises2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 24 mg, 32 mg, 48 mg or 64 mg of hydromorphone hydrochloride. 
Postupak prema zahtjevu 45, naznačen time da oblik davanja sadrži 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 24 mg, 32 mg, 48 mg ili 64 mg hidromorfon hidroklorida.
In another embodiment, an aforementioned method is provided wherein the oxidized carbohydrate moiety of the therapeutic protein is located in the activation peptide of the blood coagulation protein. 
Postupak prema zahtjevu 2, pri čemu kada je terapeutski protein protein zgrušnjavanja krvi, oksidirani dio karbohidrata terapeutskog proteina je lociran u aktivacijskom peptidu spomenutog proteina zgušnjavanja krvi.
A compound of formula (I) wherein ring B and the pyrimidine to which it is fused form a ring system selected from wherein 
R5 (1) naznačen time da prsten B 1 pirimidin na koji je kondenziran tvore prstenasti sustav odabran od
storing the G-CSF-formulation obtained in step (b) in the frozen state over a period of at least one month; 
(c) pohranjivanje G-CSF-sastava dobivenog u koraku (b) u zamrznutom stanju na vremenski period od najmanje mjesec dana; 1
The method of claim 1, wherein the thermochemical reaction is shifted into the pay zone after the pay zone is heated to about 300° C. 
Postupak prema bilo kojem od patentnih zahtjeva 18 do 22, naznačen time, da se termokemijska reakcija pomiče u zonu iskoristivosti nakon što se zona iskoristivosti zagrije do oko 300 "C.
The invention relates to pellets containing venlafaxine hydrochloride and a process for the preparation thereof. 
Izum se odnosi na granule koje sadrže venlafaksin hidroklorid i na postupak njihova priređivanja.
The user then goes to the bow, and releases the line from the cleat, and slips it off from the buoy. 
Tada korisnik odlazi na pramac, te otpušta uže s prednjeg dijela plovila, te ga uklanja s plutače.
The formulation will typically comprise a therapeutically effective amount of the or each drug which may be from about 0.01 wt % to about 99 wt %, based on the total weight of the formulation. 
Formulacija lijeka s odloženim otpuštanjem sukladno u jednom od prethodnih patentnih zahtjeva, naznačeno time, da je pufer prisutan u unutarnjem sloju u količini od 0,1 wt % do 20 wt % na temelju suhe težine trećeg polimernog materijala.
In another embodiment, said first solvent is selected from the group consisting of xylene, N-methylpyrrolidinone, Dimethylsulfoxide, diphenyl ether, Dimethylacetamide, and mixtures of 2 or more thereof. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedeno prvo otapalo se bira iz skupine koju čine ksilen, V-metilpirolidinon, dimetil-sulfoksid, difenil-eter, dimetilacetamid, te smjese 2 ili više njih.
Showing the continuous bridging dowel (7) connected at regular intervals (19) to the upper and lower portion, and the drop plate (18) positioned in between the corrugated plates at the lower portion of the expansion joint. 
Kompenzacijski spoj prema zabtjevu 1, saznačen time, što sidreni čep (7) ima izmjenične spojne točke (19) u pravilnim intervalima na odgovarajući gornji i donji dio kompenzacijskog spoja.
A container according to any one of the preceding claims, characterized in that at least the fluid collecting lip (7) and/or the lid (4) are made from an elastic material, such as plastic. 
Spremnik prema bilo kojem od prethodnih zahtjeva, naznačen time što je barem rub za skupljanje tekućine (7) i/ili poklopac (4) napravljen od elastičnog materijala, kao što je plastika.